SG11201609108TA - Antibody gene expression-secretion system - Google Patents
Antibody gene expression-secretion systemInfo
- Publication number
- SG11201609108TA SG11201609108TA SG11201609108TA SG11201609108TA SG11201609108TA SG 11201609108T A SG11201609108T A SG 11201609108TA SG 11201609108T A SG11201609108T A SG 11201609108TA SG 11201609108T A SG11201609108T A SG 11201609108TA SG 11201609108T A SG11201609108T A SG 11201609108TA
- Authority
- SG
- Singapore
- Prior art keywords
- gene expression
- antibody gene
- secretion system
- secretion
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014095440 | 2014-05-02 | ||
PCT/JP2015/002133 WO2015166641A1 (ja) | 2014-05-02 | 2015-04-17 | 抗体遺伝子の発現・分泌システム |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201609108TA true SG11201609108TA (en) | 2016-12-29 |
Family
ID=54358387
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201809464RA SG10201809464RA (en) | 2014-05-02 | 2015-04-17 | Antibody gene expression-secretion system |
SG11201609108TA SG11201609108TA (en) | 2014-05-02 | 2015-04-17 | Antibody gene expression-secretion system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201809464RA SG10201809464RA (en) | 2014-05-02 | 2015-04-17 | Antibody gene expression-secretion system |
Country Status (8)
Country | Link |
---|---|
US (1) | US10344093B2 (de) |
EP (1) | EP3138907B1 (de) |
JP (1) | JP6573398B2 (de) |
KR (1) | KR20160147778A (de) |
CN (1) | CN106536738B (de) |
CA (1) | CA2947529C (de) |
SG (2) | SG10201809464RA (de) |
WO (1) | WO2015166641A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170088866A (ko) * | 2014-12-03 | 2017-08-02 | 가부시키가이샤 아네로파마·사이엔스 | 공발현 플라스미드 |
WO2017203051A1 (en) * | 2016-05-26 | 2017-11-30 | University College Cork - National University Of Ireland, Cork | An engineered gram positive bacterium |
JPWO2019124461A1 (ja) * | 2017-12-19 | 2020-12-24 | 国立大学法人北海道大学 | 抗体断片多量体分子、医薬品、抗腫瘍剤、自己免疫疾患治療剤及び抗体断片多量体分子の作製方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1264885A4 (de) | 2000-02-22 | 2007-02-21 | Med & Biological Lab Co Ltd | Antikörperbibliothek |
EP1227152A1 (de) | 2001-01-30 | 2002-07-31 | Société des Produits Nestlé S.A. | Bakterienstamm und Genom des Bifidobacteriums |
JP2006180708A (ja) | 2003-03-31 | 2006-07-13 | Institute For Antibodies Co Ltd | 抗体作製方法 |
US8535939B2 (en) | 2010-01-29 | 2013-09-17 | Anaeropharma Science, Inc. | Transfection vector |
JP2010035472A (ja) | 2008-08-04 | 2010-02-18 | Shizuoka Prefecture | Sst−rex法を用いた新規のがん抗原特異的抗体遺伝子スクリーニング方法 |
WO2013065869A1 (en) * | 2011-11-02 | 2013-05-10 | Ajinomoto Co.,Inc. | Method for secretory production of protein |
CA2947525C (en) | 2014-05-01 | 2023-09-05 | Anaeropharma Science, Inc. | Heterologous polypeptide expression cassette |
-
2015
- 2015-04-17 SG SG10201809464RA patent/SG10201809464RA/en unknown
- 2015-04-17 EP EP15786443.0A patent/EP3138907B1/de active Active
- 2015-04-17 KR KR1020167030336A patent/KR20160147778A/ko not_active Application Discontinuation
- 2015-04-17 SG SG11201609108TA patent/SG11201609108TA/en unknown
- 2015-04-17 US US15/308,452 patent/US10344093B2/en active Active
- 2015-04-17 CN CN201580021519.0A patent/CN106536738B/zh active Active
- 2015-04-17 JP JP2016515854A patent/JP6573398B2/ja active Active
- 2015-04-17 WO PCT/JP2015/002133 patent/WO2015166641A1/ja active Application Filing
- 2015-04-17 CA CA2947529A patent/CA2947529C/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6573398B2 (ja) | 2019-09-11 |
EP3138907A4 (de) | 2017-11-01 |
CA2947529C (en) | 2022-06-21 |
EP3138907B1 (de) | 2020-02-26 |
KR20160147778A (ko) | 2016-12-23 |
US10344093B2 (en) | 2019-07-09 |
CN106536738B (zh) | 2019-12-10 |
EP3138907A1 (de) | 2017-03-08 |
CN106536738A (zh) | 2017-03-22 |
SG10201809464RA (en) | 2018-11-29 |
US20170218072A1 (en) | 2017-08-03 |
WO2015166641A1 (ja) | 2015-11-05 |
CA2947529A1 (en) | 2015-11-05 |
JPWO2015166641A1 (ja) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252004B (en) | Ether-substituted antibody | |
IL250583A0 (en) | Anti-tigit antibodies | |
SG11201703403TA (en) | Anti-tim-3 antibodies | |
SG11201703346PA (en) | Anti-tim-3 antibodies | |
LT3095034T (lt) | Kibernetinio saugumo sistema | |
IL252422B (en) | Effector-deficient anti-cd32a antibodies | |
GB201403908D0 (en) | Communicatioon system | |
IL291164A (en) | Anti-nme antibody | |
IL250374A0 (en) | Antibodies against ceramide | |
GB201410520D0 (en) | Antibody | |
PL3183174T3 (pl) | Układ do pipetowania | |
IL249254B (en) | Gene expression system | |
SG11201700922YA (en) | Anti-orai1 antibody | |
SG11201609108TA (en) | Antibody gene expression-secretion system | |
GB201411097D0 (en) | 329 - octo-lateral system | |
GB201419089D0 (en) | Anti-TIM-3 antibodies | |
GB201419092D0 (en) | Anti-TIM-3 antibodies | |
GB201417614D0 (en) | Antibodies | |
GB201418776D0 (en) | Antibody | |
GB201414270D0 (en) | Antibodies | |
GB201413745D0 (en) | Antibody | |
GB201411319D0 (en) | Antibody | |
GB201405775D0 (en) | Antibodies | |
GB201407535D0 (en) | Antibody Drug - Conjugates | |
GB201409787D0 (en) | System |